O. Yu. Sosnina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
O. Yu. Sosnina has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alevtina Nikolaeva
JSC "NPO "Microgen
2 shared publications - Kseniya A. Subbotina
E. A. Wagner Perm State Medical University, Ministry of Health of the Russian Federation
2 shared publications A. E. Ershov
НПО «Микроген
1 shared publication- A. V. Ankudinova
354 Military Clinical Hospital
1 shared publication D. M. Trofimov
НПО «Микроген
1 shared publication- E. A. Bykova
JSC "NPO "Microgen
1 shared publication
Latest Publications
- Open Access
- 15 February 2020
- Published by EKOlab in Russian Clinical Laboratory Diagnostics
- Vol. 65 (2) , 90-94
STUDYING THE POSSIBILITY OF USING IMMUNO-ENZY TEST SYSTEM FOR EVALUATING ANTI-PERTUSSIS IMMUNITY
A research objective - to study the possibility of using the ELISA Anti-K enzyme immunoassay system to evaluate anti-pertussis immunity. A comparative assessment of the content of co-crank antibodies in the blood serum of adults, pregnant women and children 6 years old in the agglutination test, in the test system “Anti-K ELISA” and test systems of foreign production was carried out. The “Anti-K” IFA test system makes it possible to detect the level of specific antibodies to both the whole cell and cell-free pertussis component of the vaccine at any stage of the vaccination cycle. This diagnostic test can be used to determine the tactics of immunization, and to assess population immunity.
- 15 February 2020
- Published by EKOlab in Russian Clinical Laboratory Diagnostics
- Vol. 65 (2) , 90-94
Open AccessSTUDYING THE POSSIBILITY OF USING IMMUNO-ENZY TEST SYSTEM FOR EVALUATING ANTI-PERTUSSIS IMMUNITY
A research objective - to study the possibility of using the ELISA Anti-K enzyme immunoassay system to evaluate anti-pertussis immunity. A comparative assessment of the content of co-crank antibodies in the blood serum of adults, pregnant women and children 6 years old in the agglutination test, in the test system “Anti-K ELISA” and test systems of foreign production was carried out. The “Anti-K” IFA test system makes it possible to detect the level of specific antibodies to both the whole cell and cell-free pertussis component of the vaccine at any stage of the vaccination cycle. This diagnostic test can be used to determine the tactics of immunization, and to assess population immunity.
- Open Access
- 28 April 2018
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 95 (2) , 68-75-75
RESULTS OF A MULTICENTER CLINICAL STUDY OF A NEW COMBINATION VACCINE DTaP-HepB+Hib PRODUCTION OF THE CPA «MICROGEN» FOR IMMUNIZATION OF CHILDREN 6 MONTHS
Aim. The aim of the study is evaluate of reactogenicity, safety and immunogenicity of the native combined vaccine DTaP-HepB+Hib. Materials and methods. Assessment of reactogenicity, safety and immunogenicity of the drug is investigated in a multicenter, comparative, randomized, simple-blind clinical trial of immunization of children 6 months (the comparator vaccine DTaP-HepB combined vaccine, Hiberix®). Results. The native combined vaccine DTaP-HepB+Hib is characterized by good tolerability, high safety profile and a pronounced immunogenicity. In terms of seroprotection, seroconversion and geometric mean titers of antibodies comparable to that used in Russia of vaccines DTP-HBV and Hiberix®. Conclusion. Vaccine DTaP-HepB+Hib can be recommended for registration in the territory of the Russian Federation for the prevention of pertussis, diphtheria, tetanus, hepatitis B and Hib-infection.
- 28 April 2018
- Published by Central Research Institute for Epidemiology in Journal of microbiology, epidemiology and immunobiology
- Vol. 95 (2) , 68-75-75
Open AccessRESULTS OF A MULTICENTER CLINICAL STUDY OF A NEW COMBINATION VACCINE DTaP-HepB+Hib PRODUCTION OF THE CPA «MICROGEN» FOR IMMUNIZATION OF CHILDREN 6 MONTHS
Aim. The aim of the study is evaluate of reactogenicity, safety and immunogenicity of the native combined vaccine DTaP-HepB+Hib. Materials and methods. Assessment of reactogenicity, safety and immunogenicity of the drug is investigated in a multicenter, comparative, randomized, simple-blind clinical trial of immunization of children 6 months (the comparator vaccine DTaP-HepB combined vaccine, Hiberix®). Results. The native combined vaccine DTaP-HepB+Hib is characterized by good tolerability, high safety profile and a pronounced immunogenicity. In terms of seroprotection, seroconversion and geometric mean titers of antibodies comparable to that used in Russia of vaccines DTP-HBV and Hiberix®. Conclusion. Vaccine DTaP-HepB+Hib can be recommended for registration in the territory of the Russian Federation for the prevention of pertussis, diphtheria, tetanus, hepatitis B and Hib-infection.